A Randomized, Double-Blind, Placebo-Controlled Trial of IkT-148009 in Untreated Parkinson's Disease
Status:
Recruiting
Trial end date:
2023-10-31
Target enrollment:
Participant gender:
Summary
This study investigates the safety and tolerability of drug IkT-148009 in untreated
Parkinson's disease volunteers (55 to 75 years old). It also looks at the pharmacokinetics of
IkT-148009 in the body and evaluates the effect of ikT-148009 on motor and non-motor features
of the disease. This 12 week study is designed to be 3:1 randomized across 3 doses of
IkT-148009 or placebo. Each participant will self-administer one of 3 doses or placebo of
IkT-148009 once daily (QD) with food for 12 weeks.